

To: All Providers Participating in the Nebraska Medicaid Program
From: Kevin Bagley, Director *KB*
Date: May 12, 2023
Re: Nebraska Medicaid to Cease Coverage for Makena Immediately

This provider bulletin is being issued to notify Nebraska Medicaid providers that **effective April 7, 2023**, Nebraska Medicaid will no longer cover Makena (hydroxyprogesterone caproate) and its generic versions.

The Food and Drug Administration (FDA) withdrew approval for Makena (hydroxyprogesterone caproate) and its generic versions on April 6, 2023, which had been approved to reduce the risk of preterm birth. The FDA stated that these drug products have not shown to be effective for the indication in which they were approved and do not have benefits that outweigh their risk to patients.

Compounded hydroxyprogesterone, which is the active ingredient in Makena, has not been reviewed by the FDA for safety and effectiveness in the risk reduction of preterm birth and continues to not be covered by Nebraska Medicaid.

Therefore, Makena and its generic versions will not be covered by Nebraska Medicaid effective April 7, 2023. Prescriptions written on or prior to April 6th, 2023, will be covered.

This provider bulletin supersedes [provider bulletin 18-01](#).

Information on the FDA's decision can be found at the following link: [Makena \(hydroxyprogesterone caproate injection\) Information](#)

Please share this information with your clinical, administrative, and billing staff.

If you have questions regarding this bulletin, please contact DHHS.MedicaidPharmacyUnit@nebraska.gov or call (402) 472-9227.

Provider Bulletins, such as this one, are posted on the DHHS website at <http://dhhs.ne.gov/pages/Medicaid-Provider-Bulletins.aspx>. Please subscribe to the page to help you stay up to date about new Provider Bulletins.